AtriCure price target raised to $25 from $20 at Leerink Leerink raised its price target for AtriCure shares to $25 citing the company's strong Q4 preannouncement. The firm believes the company's momentum is sustainable into 2014 and keeps an Outperform rating on the name.
AtriCure names Douglas Seith as COO and Andy Wade as CFO AtriCure, Inc. announced that Douglas Seith will assume the role of COO. Douglas Seith will now be responsible for all global commercial organizations as well as education and clinical science programs. The company also announced that Andy Wade has been promoted to senior VP and CFO.